Jade Biosciences (JBIO) Company presentation summary

Strategic focus and mission

• Focused on developing best-in-class therapies for autoimmune diseases, targeting critical unmet needs.

• Pipeline built on assets licensed from Paragon Therapeutics, leveraging advanced antibody discovery.

• Mission centers on urgency to deliver disease-modifying therapies enabling clinical remission.

Financial position and capitalization

• Holds $311 million in cash, with a projected runway into the first half of 2028.

• Total outstanding shares and equivalents as of March 31, 2026, are 70,745,453.

Pipeline overview and milestones

• Lead programs: JADE101 (anti-APRIL for IgAN), JADE201 (anti-BAFF-R for systemic autoimmune diseases), and JADE301 (undisclosed target).

• JADE101: Phase 1 interim data in Q2 2026, Phase 2 interim data in 2027, Phase 3 initiation in 1H 2027.

• JADE201: Interim Phase 1 data expected in 2027; Phase 1 initiation in 1H 2027.

• JADE301: Exclusive option to license; Phase 1 initiation planned for 1H 2027.